ReviewOncogene1999
Mouse models of prostate cancer.
Review in Oncogene, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Alterations in Tumor Aggression Following Androgen Receptor Signaling Restoration in Canine Prostate Cancer Cell Lines.International journal of molecular sciences · 2024Article
- Diverse landscape of genetically engineered mouse models: Genomic and molecular insights into prostate cancer.Cancer letters · 2024Review
- Molecular Similarities and Differences between Canine Prostate Cancer and Human Prostate Cancer Variants.Biomedicines · 2023Review
- Tomatoes, Lycopene, and Prostate Cancer: What Have We Learned from Experimental Models?The Journal of nutrition · 2022Review
- Molecular characterization of human papillomavirus and mouse mammary tumor virus-Molecular and clinical oncology · 2022Article
- 2,3,7,8-Tetrachlorodibenzo-p-dioxin has both pro-carcinogenic and anti-carcinogenic effects on neuroendocrine prostate carcinoma formation in TRAMP mice.Toxicology and applied pharmacology · 2016Article
- Article
- ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors.Cancer cell · 2015Article
- A C-14 labeled Py-Im polyamide localizes to a subcutaneous prostate cancer tumor.Bioorganic & medicinal chemistry · 2014Article
- Expression of a Y-located human proto-oncogene TSPY in a transgenic mouse model of prostate cancer.Cell & bioscience · 2014Article
- Transmembrane prostatic acid phosphatase (TMPAP) interacts with snapin and deficient mice develop prostate adenocarcinoma.PloS one · 2013Article
- Low systemic testosterone levels induce androgen maintenance in benign rat prostate tissue.Journal of molecular endocrinology · 2013Article
- Therapeutic targeting of redox signaling in myofibroblast differentiation and age-related fibrotic disease.Oxidative medicine and cellular longevity · 2012Review
- Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model.Biochemical pharmacology · 2009Article
- Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model.Gene therapy · 2002Article
- Prostatic intraepithelial neoplasia in genetically engineered mice.The American journal of pathology · 2002Article
- Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium.Proceedings of the National Academy of Sciences of the United States of America · 2001Article
- Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia.Oncogene · 2000Article
- RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathogenetic basis of prostate cancer remains highly elusive; its clarification could be facilitated greatly by laboratory and clinical models of the disease. Although the genetically manipulated mouse has been invaluable for the modeling of other human cancer types, it has fared less well with respect to prostate cancer. Nevertheless, several highly valuable transgenic models exist and are highlighted in this review. Emerging reagents and strategies may allow us to use the mouse more effectively to define the molecular, cellular and physiological events that lead to prostate cancer initiation and progression.
Indexed as
Identifiers
10498888What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.